Small-molecule NNMT inhibitor sold alongside peptides for fat loss and energy; no human data.
Safety tier
Caution
strict bar
Positive
41%
of 28 reports
Per month
≈ €72–1440
injected
Rank
#22
of 61 research peptides
At a glance
Onset
Some feel energy (sweating, longer workouts) at the first injected dose; many feel nothing at 1-20 mg, and oral users report effects only after weeks or after adding NMN.
Lasts
Taken once daily; users describe all-day energy from a morning dose, and insomnia at 80 mg.
Access
Grey market
Strict case
Novel systemic enzyme inhibitor with zero human safety data; unknown long-term metabolic and methylation effects.
Best effects
Energy (anecdotal) · fat loss alongside GLP-1s (confounded)
Downsides
No clear effect for many · unstable once reconstituted · injection reactions · expensive at high doses
Typical use
50-150 mg/day oral, or 1-20 mg injected (no consensus). Users report 5–31 mg/day (median 5 mg, n=12).
Stacked with
Stacked with
Retatrutide or other GLP-1s: The main use case: taken to offset GLP-1 fatigue and speed fat loss, which leaves its own effect unmeasurable. · NMN or NAD+: Rationale is that blocking NNMT spares nicotinamide for NAD+; one oral user only felt it after adding 1 g/day NMN. · MOTS-c and SS-31: Cycled with or after MOTS-c in 'mitochondrial' stacks; several users cannot tell the compounds apart.
Safety
Watch
No human safety data at all; chronic systemic enzyme inhibition alters methylation (SAM) and NAD+ salvage pathways with unknown long-term effects · Not lawful for 503B compounding (FDA warning letter Jan 2026)
Tier by safety barStrict CautionBalanced CautionEvidence only Clean
Seen harm0 of 3
Mechanism1 of 3
Data gap3 of 3
Silent harm2 of 3
Product3 of 3
Never if
Pregnancy or breastfeeding (no human reproductive data)
Why each score
Seen harm 0/3
No human study exists; the two bad first-hand reports (a blood pressure of 77/56 after injecting it with three other compounds, and two days of diuresis from a product of doubtful identity) are confounded and resolved.
Some swear it offsets GLP-1 fatigue and 'shreds abs'. Just as many ran it 11 weeks, or 50-100 mg oral, without being able to tell. Nearly everyone confounds it with retatrutide, tesamorelin and diet. Reconstituted stability is poor, and a few report reactions. Roughly half feel nothing.
Paired with Reta, it definitely counteracts the sluggishness one feels in the first two months of taking any GLP agonist. Once this stuff builds up in your system, it really does give you a good clean boost of daily energy without affecting your sleep.
Glowing2 mg/day rising to 5 mg/day · Injection · one full cycle
on retatrutide and other peptides; body fat from 30%+ to under 16%
Been taking mots-c on its own and haven't felt much. Added 1mg 5amino yesterday and had my hardest workout and had to drag myself out of the gym. Then I got home and immediately went for a run.
About a couple of hours after taking it, I started urinating heavily and continuously. This, along with a feeling of tension in the pelvic area, went on for two days.
Bad reaction50 mg · Oral
UK seller advertising third-party testing; user suspects the product was not genuine and sent it for lab analysis
Research vials (5-50 mg), oral capsules and bulk powder sold as a 'peptide' though it is a small molecule; FDA has told a 503B outsourcer it is not eligible for compounding.
A month at 1–20 mg/day costs ≈ €72–1440 from XL Peptides at €2.39/mg, as no shop scoring 4 of 5 on trust lists it. At the 5–31 mg/day users report, ≈ €360–2240.
No trusted shop in the EU lists it; every listing is on the buy page.
Studies
Evidence
Animal only
Babula et al. 2024: NNMT inhibition mitigates obesity-related metabolic dysfunctionanimal · 2024 28 days of daily 5A1MQ in obese mice limited fat gain, improved insulin sensitivity and fatty liver, with pharmacokinetics for oral and subq dosing. By the developer (Ridgeline Therapeutics); no human trial of 5-amino-1MQ has been published.
The peptide's chain of amino acids from its start (the N-terminus) to its end, one bead and one letter for each: A alanine, C cysteine, D aspartic acid, E glutamic acid, F phenylalanine, G glycine, H histidine, I isoleucine, K lysine, L leucine, M methionine, N asparagine, P proline, Q glutamine, R arginine, S serine, T threonine, V valine, W tryptophan, Y tyrosine. A modification such as an N-acetyl cap or a C-terminal amide changes how long it lasts in the body. Length tells related peptides apart, from a two-residue dipeptide like carnosine to a 43-residue protein like thymosin beta-4, and predicts neither effect nor safety.
Report grades
Every first-hand Reddit or X report is graded on its own, from glowing through positive, mixed, nothing and negative to bad reaction, and the bar shows how those grades split. Posts that look vendor-adjacent stay on the peptide's page but are left out of the counts.
GlowingPositiveMixedNothingNegativeBad reaction
% positive
The share of a peptide's graded Reddit and X reports that are glowing or positive, vendor-adjacent posts left out. A peptide with few reports is pulled toward the average of all reports, as if it had eight average ones besides its own, so two glowing posts cannot top the list. Peptides rank by this figure, those with no graded report yet after those with one, and Avoid ones after every other entry.
Researcher estimate
No first-hand report of this peptide has been graded yet, so the figure is the researchers' own rating out of 10 from what they read about it. It ranks after every peptide with graded reports until its own arrive.
Safety tier
Each peptide is tiered Clean, Caution or Avoid from its five risk axes under the chosen safety bar. An Avoid peptide carries a real risk of harm, a plausible route to serious harm rather than mere unpleasantness, so it stays listed with the reason but ranks behind every other entry, however good its reviews.
Safety bar
The safety bar sets how much risk it takes to rate a peptide Avoid. Strict: out on any serious mechanism with little human data, or any documented serious harm. Balanced: out on documented serious harm (unless it is obvious, reversible and from a regulated product), or a serious mechanism whose harm would be silent with no human data at all. Evidence only: out only on documented serious harm in humans that is lasting, delayed or from grey-market product.
Seen harm
Documented serious adverse events in humans, from 0 for none despite real exposure to 3 for deaths or several well-documented serious harms. Serious means a hospital or emergency visit or harm lasting weeks, so a headache or a bad night does not count.
Mechanism
A plausible biological route to serious harm at the doses people use, such as growth-factor signalling, hormone-axis suppression, heart or blood-pressure effects or immune activation. It runs from 0 when none is known to 3 when a dangerous pathway has been shown in living animals.
Data gap
How little human safety data exists for the molecule actually sold, from 0 for an approved drug with large trials and years of use to 3 for no human safety data at all. A modified analogue does not inherit its parent's trials.
Silent harm
Whether the feared harm would show quickly or stay hidden, from 0 when it is obvious and goes on stopping to 3 when it is silent and delayed, like tumour promotion or slow organ damage. User reports cannot reveal a harm that takes years to appear, so a high score here limits what good reviews can tell you.
Product
The risk of what people actually buy, from 0 for a regulated pharmacy or supplement product taken by mouth or on the skin to 3 for a grey-market injectable. In one dataset of 6,441 grey-market samples, 42–71% failed basic quality criteria and 15% carried endotoxin; taken by mouth or in the nose, a pack avoids the injection risks.
Evidence
The strongest kind of study behind the peptide's effects, from an approved drug through human controlled trials and small human studies to animal work or nothing of its own. Animal results often fail to carry over to people.
Access
How people get it: as an approved drug, a compounded prescription, an over-the-counter supplement or from the grey market, where nobody checks the vial. The channel decides both the legal position and the risk of a bad batch.
Price per month
Thirty days of the typical dose, from its low end to its high end, priced at the listing a careful buyer would choose: in stock, from a shop scoring 4 of 5 on trust (third-party tested where no score is set), failing that 3, a pure pack before a blend, a European shop first, then the cheapest per mg. The range is the dose's, not the shops'. A per-dose amount counts once a day unless the dose says otherwise. Prices are in euros at ECB rates of 2026-10-29, before shipping; the shop table keeps each listing's price per mg, per gram for bulk supplements. Where no listing can be priced the researchers' own estimate stands in, and says so.
Dose users report
The middle half of the daily doses stated in at least five first-hand reports, vendor posts left out. Where its middle sits more than twice above or below the declared dose, the month is priced at it as well, since what people take is what they pay for.
Shop trust
Each shop's trust on a 1–5 scale, read from its testing and its reputation: 1 for serious red flags (fabricated COAs, scam reports, impersonation, a closed shop), 2 for no public testing, a new shop or active complaints such as seized parcels, 3 for its own COAs or a short track record, 4 for verified third-party testing or a strong reputation, and 5 for third-party batch reports that name the shop, with years of good independent reputation. A shop without a score counts third-party batch testing as 4, its own COAs as 3 and no public tests as 2.
Best value
Within a category or a goal, a peptide that no other beats on both counts: none is rated more positively for the same or a lower monthly price, and none costs less for the same or a higher rating. The chart joins these into the best-value line; the cheapest of them and the best-rated of them both make it, so the line spans the trade-off from cheap to best. Avoid entries never count, and a peptide needs both a % positive and a price to be compared.
Testing
Whether the shop publishes lab results: third-party tested means an independent lab checks each batch, own COA means the shop's own certificate of analysis, and no public tests means neither. A certificate shows purity, not safety.
Added peptide
Some packs sold under one peptide's name hold a second one, such as 5 mg GHK-Cu in a nasal kit, stated only in the description. Sprayed in the nose or injected it reaches the blood like an injection, so it carries the risk of that route and is tiered as the injectable form, whatever its tier on the skin. A pack whose page gives no contents list may hold more than its name.